
|Videos|May 3, 2022
Aerie Pharmaceuticals continues their work in dry eye and glaucoma markets
Author(s)Kassi Filkins
Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, gives a company update on the various clinical trials in the pipeline.
Advertisement
Aerie Pharmaceuticals has multiple clinical trials in the pipeline for dry eye and glaucoma.
Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, shares a brief update on those.
Key pipeline highlights:
- After a successful phase 2, AR-15512 (0.003%), Aerie's novel dry eye product candidate, advances to phase 3 later this quarter.
- In late March, a phase 4 program kicked off with Aerie's product Rocklatan, Aerie's FDA-approved once-daily eye drop for the treatment of glaucoma. The phase 4 study is seeking to show data to demonstrate that it is the most powerful one drop, once a day formulation for the treatment of glaucoma.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Precise Bio completes procedure using PB-001, a 3D-bioprinted corneal implant
2
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
3
EyePoint receives second consecutive positive recommendation from DSMC
4
Defining Retinal Vascular Diseases AMD, DME, RVO
5

















































.png)


